Board of Directors
The Company’s Board of Directors is comprised of four members.

John Celentano

Mr. Celentano serves as Chair to our Board of Directors. Mr. Celentano works as an advisor to the pharmaceutical industry. With over 30 years of experience in the industry, he has held various senior leadership positions at Bristol-Myers Squibb including: President, Bristol-Myers Squibb Healthcare Group (Mead Johnson Nutrition, ConvaTec, and Medical Imaging) and Regional President roles in Emerging Markets/Asia Pacific, Latin America/Canada, and UK/Northern Europe. He serves on the Boards of Teligent, Inc. (NASDAQ:TLGT) and privately held JJ White Inc. and YourEncore Inc. He is Vice-Chairman of CMMB, an international nonprofit healthcare organization. Mr. Celentano holds a B.A. from the University of Delaware and an M.B.A. from Drexel University.

Geoffrey M. Glass

Geoffrey M. Glass is our President and CEO, and a member of the Board of Directors. Prior to this he was President of Clear Sciences, LLC, a Life Sciences focused management consulting company. He has also served on the Board of Directors of Locus Biosciences, a leading biotech company utilizing CRISPR technologies for precision medicines.
Earlier, Mr. Glass was the President of Banner Life Sciences, one of the stand-alone business units of Patheon Pharmaceuticals. Banner Life Sciences developed, manufactured and commercialized prescription pharmaceuticals, OTC and nutritional products, for markets in the Americas and Europe. Prior to his role leading this business unit, he was Executive Vice President of Sales and Marketing for Patheon Pharmaceuticals from 2009-2012.
Prior to joining Patheon in 2009, Mr. Glass spent almost five years as a senior executive at Valeant Pharmaceuticals. He was Senior Vice President, Asia Region at Valeant, and in this role had P&L responsibility for over 250 prescription pharmaceuticals across 14 countries. Prior to his Asian role, Mr. Glass served Valeant as its Senior Vice President and CIO. In each of these roles he was a member of the company’s executive committee.
Mr. Glass began his career as a consultant in the Life Sciences practice for what was formerly Ernst & Young and later became Cap Gemini.

Patrick Gray

Patrick Gray has served as a member of our Board of Directors since 2012. Mr. Gray brings extensive experience in accounting and financial reporting to our Board, having spent over 37 years with PricewaterhouseCoopers LLP (PwC) until his retirement in 2009. He is a Certified Public Accountant who spent 25 years as an Audit Partner serving clients ranging from Fortune 500 companies and multi-national companies to rapid-growth companies pursuing an initial public offering (IPO). At the time of his retirement, he served as the lead partner for the PwC U.S. firm Corporate Governance Group. Prior to that time, he held various other leadership positions with the firm, including leadership of the PwC U.S. High Technology Group. Mr. Gray earned a B.S. from The Wharton School of Business at the University of Pennsylvania and is a Certified Public Accountant.

Dennis Langer, M.D., J.D.

Dennis H. Langer has served as a member of our Board of Directors since February 2012. Dr. Langer brings over 25 years of experience in the pharmaceutical, biotechnology, and diagnostics industries in areas that include research & development, global and local marketing, and corporate development. Dr. Langer has served as a director of several public and private specialty pharmaceutical, biotechnology and diagnostic companies, and has been CEO and/or co-founder of several health care companies. From 2005 to 2010, Dr. Langer served as a Managing Partner of Phoenix IP Ventures, a private equity/venture capital firm specializing in life sciences. Previously, he was President, North America, of Dr. Reddy’s Laboratories Limited. From September 1994 until January 2004, Dr. Langer held several high-level positions at GlaxoSmithKline plc, and its predecessor, SmithKline Beecham including, most recently, as a Senior Vice President of Research & Development. Before that, Dr. Langer was President and CEO of Neose Technologies, Inc., and previously held research & development and marketing positions at Eli Lilly, Abbott Laboratories and GD Searle. At the beginning of his career, he was Chief Resident in Psychiatry at Yale University School of Medicine and held clinical fellowships at Harvard Medical School and the National Institutes of Health (NIH). Dr. Langer serves on the Board of Directors of Myriad Genetics, Inc., Dicerna Pharmaceuticals, Inc., and several private companies. Dr. Langer has also served as a Director of Myrexis, Inc., Auxilium Pharmaceutics, Inc., Sirna Therapeutics, Inc., Pharmacopeia, Inc., and Cytogen Corporation. He is a Clinical Professor in the Department of Psychiatry, Georgetown University School of Medicine. Dr. Langer received a J.D. from Harvard Law School, an M.D. from Georgetown University School of Medicine, and a B.A. in Biology from Columbia University.

Sancilio & Company, Inc.
Google+   Likedin